Renal Function Considerations for Stroke Prevention in Atrial Fibrillation

Wednesday, March 28, 2018, 1:00PM ET

Presenters:
John Fanikos, RPh, MBA
Kurt Mahan, PharmD
Paul Dobesh, PharmD, FCCP, BCPS

Renal impairment increases risk of stroke and systemic embolic events and bleeding in patients with atrial fibrillation. Direct oral anticoagulants (DOACs) have varied dependence on renal elimination, magnifying the importance of appropriate patient selection, dosing, and periodic kidney function monitoring. In randomized controlled trials of nonvalvular atrial fibrillation, DOACs were at least as effective and associated with less bleeding compared with warfarin.

Read the full article from the American Journal of Medicine. Register for our webinar to hear in depth discussion from the authors.

Anticoagulation Therapy
Editors: Joe Lau, MD; Geoffrey Barnes, MD; Michael Streiff, MD
This book presents the latest evidence and guidelines supporting the use of anticoagulant therapy for various clinical scenarios. Organized in two parts, this book reviews the pharmacological properties of various anticoagulants and details the clinical applications of anticoagulant therapy. Drugs such as warfarin and unfractionated heparin, as well as parenteral and direct oral anticoagulants are discussed in terms of their pharmacokinetics, drug-disease interactions, dosing strategies, and risk considerations. Clinical applications of anticoagulant therapy in disorders such as acute coronary syndromes, atrial fibrillation, and thrombophilia and in special populations such as pregnant women, the elderly, and in the patient with cancer are highlighted.

Clinical vignettes, algorithms, clinical pearls, and self-assessment questions are integrated throughout the book. Featuring contributions from authorities in the field, Anticoagulation Therapy is an essential resource for cardiologists, vascular medicine specialists, hematologists, internists, and all other healthcare professionals who prescribe anticoagulants.

Email holly.klokis@springer.com directly for 20% off!

---

**SAVE THE DATE**
**APRIL 11-13, 2019**
**THE DIPLOMAT BEACH RESORT**
**FORT LAUDERDALE**

---

**2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants**

**Wednesday, May 9, 2018, 12:00PM ET**

**Guest Discussant:** Adam Cuker, MD

**Moderators:**
Tracy Miniciello, MD; Sara Vazquez, PharmD; Diane Wirth, ANP, CACP

The primary goal of this decision pathway is to guide the management of acute bleeding in patients treated with oral anticoagulants (OACs) and to supplement the 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Non-Valvular AF.

Read the full article from the Journal of American College of Cardiology. Register for our webinar to hear a review from one of the authors and a discussion with members of our board.
Follow us on twitter and Facebook @AnticoagForum

AC Forum Boot Camp | April 23-24 | Austin, TX
Only 20 spots remain!!

Join us for this unique meeting with a comprehensive curriculum covering essential aspects of anticoagulation, disease state, and drug management. Our program provides the opportunity to learn from, and engage with, some of the leaders in the anticoagulation space.

Enjoy small group learning with some big faculty names including 10 AC Forum board members. We limit enrollment to a small group to allow more personal interaction with our expert faculty and with your peers.

Boot Camp offers 11.25 contact hours of education credit for Physicians, Nurses and Pharmacists. Registration is $399.

PERT Consortium 4th Annual Symposium
Pulmonary Embolism

This annual two-day AMA PRA/ANCC-accredited conference entitled, Pulmonary Embolism: What is Known, and What We Need to Know: A State of the Art and Scientific Update', is designed for practicing clinicians who regularly care for patients with pulmonary embolism (PE), as well as those who are interested in studying the pathophysiology, epidemiology, diagnosis, medical and interventional management, novel treatment paradigms, and outcomes of PE.

Register now for Early Bird discount!

Find out more about Anticoagulation Forum
acforum.org
The Anticoagulation Forum is a multi-disciplinary nonprofit organization of healthcare professionals that will improve the quality of care for patients taking antithrombotic medications.

Not a member yet? Join us at acforum.org
Follow us on twitter and Facebook @AnticoagForum

Thank You to Our Newsletter Sponsors

- Bristol-Myers Squibb
- Pfizer
- Daiichi-Sankyo
- Janssen
- Boehringer Ingelheim
- Roche